Eli Lilly (LLY) continues to
grow and
impress investors, with its value significantly increasing for those who invested in the stock as early as 15 years ago. This growth is driven by widely
utilized drugs such as GLP-1, even if diabetic drug sales fell short. Among major investment firms, many have enhanced their stakes, such as
Vontobel Holding, Values Added Financial, and Core Alternative Capital, asserting a strong confidence in the biopharmaceutical giant. An
expansion of partnerships is also noted, with a specific highlight on its partnership with AdvanCell for groundbreaking cancer therapies. It's also being acknowledged as a leading
long-term growth stock and one of the best dividend growth companies. Moreover, Lilly remains focused on the development of its
drug pipeline, having achieved substantial success with its drug Omvoh® (mirikizumab-mrkz) for Crohn's disease. Overall, the company appears robust and potentially worthwhile for investors.
Eli Lilly LLY News Analytics from Thu, 05 Dec 2024 08:00:00 GMT to Sat, 15 Feb 2025 21:17:00 GMT -
Rating 9
- Innovation 7
- Information 9
- Rumor 0
